Oxford Biomedica PLC Total Voting Rights (3857K)
September 01 2021 - 5:48AM
UK Regulatory
TIDMOXB
RNS Number : 3857K
Oxford Biomedica PLC
01 September 2021
Oxford Biomedica
Total Voting Rights
Oxford, UK - 01 September 2021: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure Guidance and Transparency Rule
5.6.1, the Company's issued share capital as at the close of
business on 31 August 2021 consisted of 82,657,246 ordinary shares
of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares
held in treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 82,657,246.
The above figure (82,657,246) may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oxford Biomedica plc under the FCA's Disclosure
Guidance and Transparency Rules.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, cell
and gene therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders and liver diseases. The
Group has also entered into a number of partnerships, including
with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Additionally the
group has signed a three year master supply and development
agreement with AstraZeneca for large-scale manufacturing of the
adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more
than 670 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVREANNFELXFEEA
(END) Dow Jones Newswires
September 01, 2021 05:48 ET (09:48 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024